Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

被引：10
|
作者：
Glajzer, Joanna [1 ,2 ,3 ,4 ,5 ]
Grabowski, Jacek P. [1 ,2 ,3 ,4 ,5 ]
Sehouti, Jatid [1 ,2 ,3 ,4 ,5 ]
Pfisterer, Jacobus [6 ]
机构：
[1] Charite Univ Med Berlin, Dept Gynecol, Berlin, Germany
[2] Charite Univ Med Berlin, Ctr Oncol Surg, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Berlin Inst Hlth, Berlin, Germany
[6] Gynecol Oncol Ctr, Kiel, Germany
来源：
CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2020年 / 21卷 / 06期
关键词：
Recurrent ovarian cancer; Treatment ovarian cancer; Surgery ovarian cancer recurrence; Chemotherapy ovarian cancer; PARP inhibitors; OLAPARIB MAINTENANCE THERAPY; DOUBLE-BLIND; OPEN-LABEL; EPITHELIAL OVARIAN; PRIMARY PERITONEAL; PHASE-3; TRIAL; BEVACIZUMAB; CHEMOTHERAPY; CARCINOMA; MULTICENTER;
D O I：
10.1007/s11864-020-00747-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Opinion statement The choice of the right treatment regimen for recurrent ovarian cancer (rOC) remains a case-by-case decision. It is based on multiple factors that involve patient characteristics and biological factors at the same time. The prioritization of factors is still subject to changes with a trend towards a more personalized medicine. Therefore, participation and engagement in clinical studies constitutes a substantial need for the future development of the treatment algorithm of rOC.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
    Joanna Glajzer
    Jacek P. Grabowski
    Jalid Sehouli
    Jacobus Pfisterer
    Current Treatment Options in Oncology, 2020, 21
  • [2] What treatment should be given to the cryopreserved ovarian tissue after thawing?
    Callejo, J
    Salvador, C
    Prats, P
    Lailla, JM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04): : 1908 - 1909
  • [3] Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
    Patel, Aashna
    Kalachand, Roshni
    Busschots, Steven
    Doherty, Ben
    Kapros, Evangelos
    Lawlor, Denise
    Hall, Neville
    Stordal, Britta K.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (07):
  • [4] Chemotherapy in recurrent ovarian cancer: What clinical benefit should be expected?
    Elfrink, S. H.
    Myers, T. K. N.
    Gold, M. A.
    Walker, J. L.
    McMeekin, D. S.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 380 - 380
  • [5] Chemotherapy in recurrent ovarian cancer: What clinical benefit should be expected?
    Myers, T. K.
    Elfrink, S. H.
    Gold, M. A.
    Walker, J. L.
    McMeekin, D. S.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S112 - S112
  • [6] Treatment options in patients with recurrent ovarian cancer
    Gadducci, A
    Conte, P
    Cianci, C
    Negri, S
    Genazzani, AR
    ANTICANCER RESEARCH, 2001, 21 (05) : 3557 - 3564
  • [7] What advice should be given to patients with a family history of colon cancer?
    Grandjouan, S
    SEMAINE DES HOPITAUX, 1996, 72 (19-20): : 589 - 593
  • [8] WHAT TREATMENT SHOULD BE GIVEN FOR AGGRESSIVE LYMPHOMAS
    COIFFIER, B
    LYON MEDICAL, 1981, 246 (20): : 421 - 422
  • [9] Counseling patients with recurrent/progressive epithelial ovarian cancer: What is the true efficacy of advanced-line chemotherapeutic regimens?
    King, E. R.
    Jazaeri, A. A.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S64 - S64
  • [10] Nonsurgical Conservative Approach for Laryngeal Cancer: What Information Should Patients Be Given?
    Russi, Elvio G.
    Numico, Gianmauro
    Merlano, Marco C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3168 - 3170
12345